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OBJECTIVES: To investigate the usefulness of National Health and Nutrition 
Examination Survey (NHANES) data for exposure estimates. To illustrate its utility, 
the relationship between biomarkers of exposure (serum cotinine) and 
cardiovascular disease (WBC, Apo lipoprotein, C-reactive protein, HDL, LDL, total 
cholesterol) among current, past, and non smokers was examined using NHANES 
2007-2010. METHODS: Data were obtained from NHANES 2007 to 2010. The study 
sample had 11, 960 respondents who were 21 years and above, answered questions 
on cigarette smoking and had complete laboratory values for their biomarkers 
measurement. The population was categorized as current, past, and non smokers. 
The exposure variable was serum cotinine concentration and the outcome variables 
were serum levels of the biomarkers listed above. Weighted survey linear 
regression was used to estimate the association between cotinine concentration 
and biomarkers levels. We also tested the models for different levels of covariates; 
age, sex, race and body mass index (BMI). RESULTS: The levels of WBC (F-value: 
38.78; P-value: <.0001) and HDL (F-value: 26.43; P-value: <.0001) showed higher 
association with cotinine levels than rest of the biomarkers. The R2for the models 
ranged from 0.039-0.261. Higher levels of WBC and lower levels of HDL were 
observed among current smokers relative to past and non smokers. BMI showed a 
high association with most of the biomarkers. The odds of lower HDL were 
significantly higher for 21-35 years age group relative to the >65 years age group. 
Non-Hispanic blacks had a significantly lower HDL than non-Hispanic whites. 
Females had significantly higher HDL than males. These results were consistent 
with that reported in the literature. CONCLUSIONS: A statistically significant 
association was observed between the biomarker of exposure (serum cotinine) and 
WBC and HDL cholesterol. There were also significant differences in the association 
within the different covariate levels.  
 
PRM53  
CLAIMS DATA ALGORITHMS FOR IDENTIFYING INCIDENT COLORECTAL 
CANCER (CRC) CASES AND CANCER DISEASE STAGE: A CRITICAL REVIEW OF 
THE LITERATURE  
Foley K1, Shi N1, Girvan A2, Ward KC3, Lipscomb J4 
1Truven Health Analytics, Cambridge, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3Emory University, Rollins School of Public Health, Atlanta, GA, USA, 4Emory University, 
Atlanta, GA, USA  
OBJECTIVES: Administrative claims data are commonly used to study CRC 
treatment patterns and outcomes. We critically review existing algorithms for 
identifying incident CRC cases and disease stage at diagnosis within claims data. 
METHODS: A literature search (1989-2012) using the terms: cancer [ti] AND 
(administrative OR claims) AND (assess [ti] or assessment [ti] or predict [ti] or 
prediction [ti] or identify [ti] or identification [ti] or validate[ti] or validation[ti] or 
agreement[ti] or agree[ti]) identified 76 articles with 27 testing algorithms. Of the 
27, two provided algorithms for identifying incident CRC cases and two 
algorithms identified metastatic CRC at diagnosis. We examine the positive 
predictive value (PPV) of each algorithm and suggest revisions for improving the 
PPV. RESULTS: Setoguchi evaluated four algorithms for identifying CRC patients. 
The first and most restrictive required combinations of ICD-9 and treatment 
codes. The second used two diagnoses within two months, the third combined 
the first and second, and the fourth required one diagnosis. Ramsey used one or 
more ICD-9 codes, the same as Setoguchi algorithm 4. The PPV ranged from 45% 
to 71% for algorithms 4 to 1, respectively. Disease stage algorithms included one 
by Anaya for identifying liver metastases (PPV= 87%) and one by Nordstrom for 
identifying metastatic disease at any site (PPV=80%). CONCLUSIONS: For 
identifying incident CRC patients, we suggest revising Setoguchi algorithm 1 to 
follow the well-tested Nattinger breast cancer algorithm with updates to 
surgical/chemotherapy codes. We also recommend fewer criteria among older 
patients, as PPV is lower for patients less likely to receive aggressive care. For 
disease stage, metastatic disease can be accurately identified with a small set of 
codes, but no studies examined algorithms for identifying CRC stages I-III. We 
recommend adapting the Smith and Shih algorithm for breast cancer disease 
staging to CRC while incorporating the metastatic codes reviewed here.  
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OBJECTIVES: The purpose of this study was to compare the medication 
compliance estimates among a sample of infliximab-treated Crohn’s disease  
(CD) using two separate data sources: medical charts and administrative claims. 
METHODS: A Mid-Atlantic regional health plan provided claims data for their CD 
population during calendar years 2006-2010. Claims were aggregated by 
gastroenterologist tax ID in order to identify providers with the largest CD 
patient panels for recruitment into a chart review study. An electronic case 
report form was developed to aid in the chart data extraction and included fields 
for demographics, anthropometrics, diagnoses, medications, diagnostic tests, 
surgical procedures, treatment dose, administered quantity, and service dates. 
Once captured, both the chart and claims data were used to quantify medication 
treatment compliance over one episode of care. RESULTS: One hundred and 
sixty-one infliximab charts were reviewed and merged with the claims data. 
Dosages and vial counts were unavailable in the claims data; therefore,  
intervals between maintenance infusions were calculated, resulting in a mean 
maintenance interval of 58 days (± 15) per patient. Regarding charts, infusion 
date, dosage, and administered quantity were all available. Approximately 83% 
of infliximab patients had a stable dose of 5 mg/kg over the course of their first 
episode of care, with a mean maintenance interval of 60 days. Dosing 
information from patient charts will be used to estimate dosage from  
claims where charts are not present in an effort to create an algorithm for 
estimating dose from administrative claims only. CONCLUSIONS: Claims  
data were less equipped to estimate biologic treatment compliance, while  
the chart data included many indicators necessary to track biologic dosing 
patterns. However, information from claims augmented charts, and provided 
details on a much larger population of biologic patients, highlighting the 
importance of utilizing both the get a better depiction of treatment, compliance, 
and costs.  
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OBJECTIVES: Administrative claims data are used to study BC treatment patterns 
and outcomes. We critically review existing algorithms for identifying incident 
BC cases and disease stage at diagnosis within claims data. METHODS: A 
literature search (1989-2012) using the terms: cancer [ti] AND (administrative OR 
claims) AND (assess [ti] or assessment [ti] or predict [ti] or prediction [ti] or 
identify[ti] or identification [ti] or validate[ti] or validation[ti] or agreement[ti] or 
agree[ti]) identified 76 articles with 27 testing algorithms. Of the 27, three 
provided algorithms for identifying incident BC cases and four algorithms 
classified BC disease stage at diagnosis. We examine the positive predictive 
value (PPV) of each algorithm and suggest revisions for improving the PPV. 
RESULTS: To identify incident BC, Warren used ICD-9 and treatment codes 
across inpatient and outpatient settings (PPV=80%), Freeman used a logistic 
regression with 36 diagnostic and procedural indicators (PPV=70%), and 
Nattinger used a 4-step process using ICD-9 and treatment codes (PPV=93%). For 
disease stage, the Yuen and Cooper papers used diagnostic codes to distinguish 
regional from distant spread of cancer, with PPVs below 60%. Smith used 
diagnoses, procedures, and medical visits to estimate equations for 
distinguishing stage IV from all other patients and stage III from patients with 
stage I/II. Trade-offs between sensitivity and PPV are made using cut-points from 
the models to classify patients into disease stage. Nordstrom’s algorithm 
identified metastatic disease using three components: a diagnosis code for 
secondary neoplasm OR any metastatic chemotherapy agent OR no G-code for 
non-metastatic disease AND G-code for metastatic disease (PPV=81%). 
CONCLUSIONS: For identifying incident BC, we recommend updating the 
Nattinger algorithm with newer codes and fewer criteria for older patients likely 
to receive less aggressive care. For disease stage, we recommend updating the 
Smith algorithm with additional codes from Nordstrom and testing higher cut-
points to maximize PPV.  
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OBJECTIVES: Osteoarthritis and atherosclerosis are both chronic inflammatory 
diseases.However, the association between osteoarthritis and the rate of major 
adverse cardiovascular events (MACEs) has never been reported (check 
literature). METHODS: Using the retrospective, observational, longitudinal study 
design, we evaluate the association between osteoarthritis and the rate of MACEs 
in subjects with essential hypertension retrieved from Taiwan National Health 
Insurance Research Dataset (NHIRD). Patients with HTN and free of pre-defined 
MACEs (MI, stroke, CHF, ESRD and PVD) in the entire course were enrolled as 
control group. In contrast, those with both HTN and OA and free of previous 
MACEs were enrolled as study group. RESULTS: Totally up to 56,607 hypertensive 
patients (aged 30-60 years) without previous MACEs at the first year (in 1996) 
were identified. There were 23,530 (41.6 %) patients with concomitant diagnosis 
of OA. The crude MACE rates were significantly higher in hypertensive patients 
with OA than those without OA (MI: 2.37% vs. 1.64 %, p<0.0001; stroke: 3.90% 
vs.3.33%, p=0.0004; CHF: 1.60% vs.1.37%, p=0.025; PVD: 10.24% vs. 4.36%, p<0.0001, 
respectively), except for ESRD (1.05% vs. 1.33%, p=0.0032). After adjusted for birth 
year and sex, the adjusted ORs (95% confidence interval (CI) and p-values) for 
MACE in patients with both OA and HTN were all significantly higher by the 
relative risk of 3.09 (2.69-3.54, p<0.0001) in MI; 2.47 (2.22-2.75, p<0.0001) in stroke; 
2.40 (2.06-2.79, p<0.0001) in CHF; 1.75 (1.48-2.08, p<0.0001) in ESRD and 4.77 (4.38-
5.19, p<0.0001) in PVD, respectively. CONCLUSIONS: Results from this study 
highlight the MACE (MI, stroke, CHF, ESRD and PVD) rates were significantly 
higher in hypertensive patients with OA than those without it.  
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OBJECTIVES: Frequently, commercial health insurance administrative claims 
databases are considered non-representative of the United States (US) 
population because they reflect only working age individuals, and their 
dependents who are currently employed. If this employment characteristic 
exists, it should be visible when large commercial administrative databases are 
compared against US Census demographic data. METHODS: This study 
compared the HealthCore Integrated Research Database (HIRD) and the 
MarketScan Database against US Demographic data for geographic region, age 
and gender. Age groups and geographic regions were coded to be consistent with 
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US census divisions: Mid-West, West, North-East and South. Data were 
abstracted from 2009; the latest year that US Census data, HIRD and MarketScan 
data were available. Patients were required to have generated at least 1 health 
care claim to be included in the analysis. RESULTS: The HIRD (n=14,794,609) and 
MarketScan (n=42,632,943) databases showed remarkable agreement between 
gender and age groups for all four geographic regions. Both MarketScan and the 
HIRD databases over represented US Census data for the age groups below 5 
years and above 30 years of age. These agreement levels were consistent across 
all four regions and two gender groups. There was close agreement from ages 5 
to 30 years for all sources. HIRD and MarketScan data under-represented the US 
Census data for age groups above age 65 years. CONCLUSIONS: The employment 
characteristic is present in both the HIRD and MarketScan databases, and can be 
quantified against the US Census. HIRD and MarketScan data are equally 
affected by the commercial database employment characteristic. The HIRD and 
MarketScan data agreement indicate that for research on specific disease or drug 
classification, it would be possible to extrapolate weighting data against US 
Census data to yield accurate estimates of disease prevalence among patients, or 
claims for coexisting and comorbid conditions and pharmacy claims.  
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OBJECTIVES: Joint replacement is one of the commonest elective procedure 
performed in the elderly veterans. Database studies assume the occurrence of 
revision to be the same side as the most recent primary, in the absence of 
laterality being captures in claims databases. A recent Medicare study found that 
such an assumption had a significant error rate with only 71% revision on the 
same side as the most recent joint replacement. METHODS: We utilized the 
Veterans Affairs (VA) administrative and clinical databases from fiscal years 2002 
to 2010. We defined the joint replacement cohort based on the presence of 
Common Procedure Terminology (CPT) codes for total knee, hip or shoulder joint 
arthroplasty (TKA, THA, TSA). We used NLP ascertainment of laterality of 
primary and revision joint replacement. RESULTS: The cohorts consisted of 
84,495 patients with 87,495 procedures. Mean age was 63 years, 94% were male; 
84% were Caucasian, 14% were African-American and 2% were other. 73,488 had 
operative notes available and constituted our analytic dataset. Joint laterality 
was established based on text data for >98% of primary and >97% of all joint 
replacement cohorts. We found that 57% of the primary TKA were right, 41% 
were left and 1% simultaneous bilateral. Similar proportions were noted for 
primary THA and primary TSA. For revision TKA, THA and TSA, similar 
proportions were noted. CONCLUSIONS: NLP can obtain the laterality of joint 
replacement surgery and this can assist in improving the quality of database 
studies of joint replacement surgery that use the VA databases.  
 
PRM59  
ESTABLISHING A WEIGHTING METHODOLOGY TO COMPUTE THE NUMBER OF 
PATIENTS WITH DISEASE USING CLAIMS DATA AND CENSUS POPULATION IN 
THE UNITED STATES  
Wasser T1, Wu B1, Ycas J2, Tunceli O1, Cziraky MJ1 
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA  
OBJECTIVES: Commercial claims databases are thought to over-represent 
working age groups and under-represent older age groups because of 
employment bias attributable to their population of working age individuals, and 
their dependents, who have employer based insurance coverage. METHODS: 
Four disease classifications (acute coronary syndromes, dyslipidemia, breast 
cancer, and major depressive disorder[MDD]), and four drugs classes (statins, 
anti-platelets, anti-estrogens and atypical antipsychotics) were used to develop 
and evaluate linear weighting methods compared to the United States (US) 
Census data. Any patient within the HealthCore Integrated Research Database 
(HIRD) with a claim for any of the disease or drug classifications during 2009 was 
eligible for this analysis. This year was selected because it was the latest year for 
which US Census data were available. Linear weighting method was used as the 
‘Weight = Estimated Population Value from the US Census/HIRD value. RESULTS: 
A total of 14,794,609 patients in the HIRD met the inclusion criteria. Weights 
were calculated for the Mid-West, West, North-East and South geographic 
regions, and were stratified by gender and age using US Census age groups. For 
example, for 1,227 North-East-based male patients, aged 15-19 years, in the HIRD 
database who were diagnosed with an MDD the weight derived from US Census 
data was 1.10, indicating that an estimated 1,353 patients in the North-East 
region with MDD. CONCLUSIONS: The number of individuals in the US 
population with any one of four disease or drug classifications can be safely 
estimated using a linear weighting methodology, which makes it possible to 
calculate estimates of the total number of patients in the US population, or by 
geographic region, and further stratified by age group and gender. Such 
estimation is useful for research requiring estimation numbers of patients with a 
disease condition or pharmacy utilization.  
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OBJECTIVES: Substantial evidence suggests that following an enhanced recovery 
after surgery (ERAS) program is effective in improving post-surgical outcomes. To 
examine the potential associations between compliance with ERAS protocol 
elements and post-op fluid use, opioid use, hospital length of stay (LOS), hospital 
costs, and readmissions, would require combining data elements from the ERAS 
program with regularly collected retrospective data elements in a large multi-
hospital database. The objective of this study was to combine information from a 
prospective dataset with a matched retrospective data source. METHODS: Duke 
University Medical Center (DUMC) collected data on colorectal surgery patients 
in order to determine eligibility for inclusion in the study. With IRB approval, we 
matched selected patients in the Premier research database on criteria of age, 
gender, discharge date, procedure date, length of stay, presence of a colorectal 
procedure during stay, and presence of a colorectal procedure. All matches were 
verified by physicians at DUMC. RESULTS: Of the 240 patients in the DUMC 
database, 206 (85.8%) matched on all variables. One other patient matched, 
except on having a colorectal procedure on an identical date. Thirteen (5.4%) 
were a match, except on length of stay. Expanding the age criteria to ±1 year, we 
were able to match 7 (2.9%) additional patients. Similarly, allowing the procedure 
date to match within ±1 day increased the total by one more patient. Eight (3.3%) 
patients required a manual match by discharge date and presence of a colorectal 
procedure during the hospital stay. The final four (1.7%) patients could not be 
matched because their discharge date was outside the range of the Premier 
database. CONCLUSIONS: Using the different matching approaches criterion, we 
were able to link nearly all patients from the DUMC prospective database to the 
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OBJECTIVES: To evaluate the use of the population-based Emilia-Romagna 
region (RER) administrative database for drug outcomes studies using as an 
example the previously documented increased mortality risk amongst new users 
of conventional versus atypical antipsychotic medications. METHODS: We 
conducted a new user cohort study among 23,681 Italian RER patients aged 65 or 
older who initiated treatment with a conventional or atypical antipsychotic 
between July 1, 2009 and June 30, 2011. The 180-day mortality was compared for 
patients in each treatment group using Cox proportional hazards models that 
were adjusted for mortality risk factors, including demographic and clinical 
characteristics, use of other medications, and measures of health services 
utilization intensity, all measured prior to antipsychotic initiation. We conducted 
a systematic review and meta-analysis of studies with similar methods against 
which we compared our results. RESULTS: Amongst 14,462 patients prescribed 
conventional and 9,212 prescribed atypical antipsychotics, we observed 2,402 
(16.6%) and 821(8.9%) deaths during follow-up, respectively. New users of 
conventional antipsychotics were older and generally had higher prevalences of 
outcome risk factors and higher health service use intensity at baseline. The 
crude hazard ratio (HR) was 1.95 (95% confidence interval [CI], 1.80-2.11), which 
decreased to 1.47 (95% CI, 1.35-1.60) after full adjustment. We identified seven 
published studies examining this association using similar methods. The pooled 
HR from these seven studies was 1.34 (95% CI, 1.28-1.39). Upon inclusion of our 
study, the meta-analysis yielded a summary estimate of 1.35 (95% CI, 1.31-1.40) 
without introducing any heterogeneity (I2 = 0%; p=0.455). CONCLUSIONS: Our 
results support the findings of previous studies and provide a refined estimate of 
the association between increased mortality amongst elderly patients taking 
conventional versus atypical antipsychotics. Our study provides support for the 
use of the RER database for pharmacoepidemiology studies.  
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OBJECTIVES: The purpose of the study was to calculate primary medication non-
adherence (PMN), using the Pharmacy Quality Alliance's (PQA) quality measure 
with retail pharmacy transaction data. Primary non-adherence is an instance 
whereby patients fail to initiate a pharmacotherapy regimen following a 
recommendation by a physician or other health care provider (a prescription). 
METHODS: De-identified, pharmacy transactional data for calendar years 2010 
and 2011 from 100 pharmacies of a pharmacy grocery chain were used. Primary 
medication non-adherence was defined as when a new medication was 
prescribed for a patient age 18 or older, but was not obtained from the pharmacy 
within 30 days. A set list of chronic medications was constructed that would 
warrant a patient needing to pick the medication up in a timely manner to begin 
therapy. Additionally, only electronic prescriptions were assessed as the data 
captured for prescription origination date and medication pickup date could not 
be genuinely accounted for in paper prescriptions. A prescription was 
categorized as new drug therapy if the medicine prescribed (or its generic 
equivalent) had not been filled for the patient by the pharmacy during the prior 
180 days. If the prescription was deemed to be a newly initiated drug therapy, it 
was included in the denominator for the measure. The numerator was populated 
when a newly initiated drug therapy or its therapeutic equivalent was not filled 
